Evidence map›Paper›PMID 42865613›Full record

ReviewFrontiers in medical technology2026

Bio-based nanophotothermal systems as smart drug delivery platforms for multimodal synergistic cancer therapy-a review.

Aleksandra Porjazoska Kujundziski

Abstract readReview
In one paragraph

Review in Frontiers in medical technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Aleksandra Porjazoska Kujundziski *Faculty of Engineering, International Balkan University, Skopje, North Macedonia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional protocols for cancer treatment are usually accompanied by serious limitations, which can be addressed using innovative, minimally invasive methods, such as photothermal therapy (PTT). But, using this method as a standalone therapy is usually accompanied by uneven heat distribution within tumor tissues, and the risk of cancer recurrence. Integrating PTT with complementary therapeutic modalities can help prevent these issues. The development of nanophotothermal systems (NPTSs) as multipurpose, multimodal platforms for smart drug delivery has greatly broadened the therapeutic landscape of cancer treatment. Additionally, recent developments in bio-based and biocompatible nanomaterials have further expanded the potential of NPTSs in clinical applications. Furthermore, NPTSs combine therapeutic functionalities and diagnostic imaging, i.e., tracking modalities, such as photoacoustic, magnetic resonance, or fluorescence imaging, to provide real-time monitoring of drug delivery and treatment response. Translation of preclinical trials into clinical applications for these systems remains challenging due to issues such as toxicity, biodegradability, scalability, standardization, and regulatory approval. This narrative review analyzes two of the most versatile natural polysaccharides, chitosan (CS) and hyaluronic acid (HA), which have complementary physicochemical and biological properties. Covering the advantages of CS and HA for the application in multifuntional and multimodal nanophotothermal systems, their complementary effects, as well as their functional implications in therapeutic settings, this work aims to create a framework that will serve as a basis for further research in optimizing the design of multifunctional drug-delivery nanosystems, and at the same time, facilitate the transition of photothermal therapy from the bench to clinical use.

Indexed as

bio-based systemscancer treatmentchitosandrug deliveryhyaluronic acidnanophotothermal systemstheranostics

Identifiers

PMID42865613
PMCPMC13655416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.